^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
GENE:

ATP5IF1 (ATP Synthase Inhibitory Factor Subunit 1)

i
Other names: ATP5IF1, ATP Synthase Inhibitory Factor Subunit 1, ATPI 2, ATPase Inhibitor, Mitochondrial, ATP Synthase F1 Subunit Epsilon, ATP Synthase Inhibitor Protein, Inhibitor Of F(1)F(O)-ATPase, ATPase Inhibitory Factor 1, ATPase Inhibitor Protein, ATPIF1, ATPIP, IF(1), IF1, IP, ATP5IF1, MGC1167, MGC8898
3ms
NMR assignments of the human homodimeric mitochondrial ATP synthase inhibitor IF1. (PubMed, Biomol NMR Assign)
Secondary structure analyses based on chemical shifts and short-range NOE patterns indicate the N-terminal half of the 81-residue IF1 is intrinsically disordered, while the C-terminal half adopts a continuous α-helix. The chemical shift assignments for human IF1 provide a foundation for future mechanistic structure-function studies and NMR-based drug screening.
Journal
|
ATP5IF1 (ATP Synthase Inhibitory Factor Subunit 1)
3ms
ATPase Inhibitory Factor 1 Drives Mitochondrial Energy Metabolic Reprogramming to Promote HCC Vasculogenic Mimicry via the ESR1/miR-20a-3p/GNAZ Pathway. (PubMed, Research (Wash D C))
G protein subunit alpha Z (GNAZ), a miR-20a-3p target protein, can promote VM by phosphorylating components of the ERK pathway. Collectively, these results delineate a novel IF1/ESR1/miR-20a-3p/GNAZ axis in HCC VM and metastasis, providing potential therapeutic targets.
Journal
|
ER (Estrogen receptor) • ATP5IF1 (ATP Synthase Inhibitory Factor Subunit 1) • MIR20A (MicroRNA 20a)
3ms
NMR assignments of the human homodimeric mitochondrial ATP synthase inhibitor IF1. (PubMed, Res Sq)
Secondary structure analyses based on chemical shifts and short-range NOE patterns indicate the N-terminal half of the 81-residue IF1 is intrinsically disordered, while the C-terminal half adopts a continuous α-helix. The chemical shift assignments for human IF1 provide a foundation for future mechanistic structure-function studies and NMR-based drug screening.
Journal
|
ATP5IF1 (ATP Synthase Inhibitory Factor Subunit 1)
4ms
Study on the effect of ATPIF1 on the anti-tumor activity of CAR-NK92 cells by regulating glycolytic capacity (PubMed, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi)
The impact of glycolytic inhibition by 2-Deoxy-D-glucose (2-DG) on CAR-NK92 antitumor capacity was examined...Conclusion ATPIF1 regulates the antitumor activity of CAR-NK92 cells through modulating glycolytic metabolism. Overexpression of ATPIF1 can enhance the antitumor efficacy of CAR-NK92 cells.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • LAMP1 (Lysosomal Associated Membrane Protein 1) • GZMB (Granzyme B) • IFIT1 (Interferon Induced Protein With Tetratricopeptide Repeats 1) • ATP5IF1 (ATP Synthase Inhibitory Factor Subunit 1) • NKG2D (killer cell lectin like receptor K1)
|
HER-2 overexpression
10ms
Mitochondrial membrane hyperpolarization modulates nuclear DNA methylation and gene expression through phospholipid remodeling. (PubMed, Nat Commun)
Sorted hyperpolarized WT and ovarian cancer cells naturally depleted of IF1 also showed phospholipid remodeling, indicating this as an adaptation to mitochondrial hyperpolarization. These data provide a new framework for how mitochondria can impact epigenetics and cellular biology to influence health outcomes, including through chemical exposures and in disease states.
Journal
|
ATP5IF1 (ATP Synthase Inhibitory Factor Subunit 1)
11ms
Acute myeloid leukemia mitochondria hydrolyze ATP to support oxidative metabolism and resist chemotherapy. (PubMed, Sci Adv)
Knockdown of ATP5IF1 conferred venetoclax resistance, while ATP5IF1 overexpression impaired F1-ATPase activity and heightened sensitivity to venetoclax. These data identify matrix ATP consumption as a cancer cell-intrinsic bioenergetic vulnerability actionable in the context of BCL-2 targeted chemotherapy.
Journal • IO biomarker
|
ATP5IF1 (ATP Synthase Inhibitory Factor Subunit 1)
|
Venclexta (venetoclax)
1year
Decoding the regulatory role of ATP synthase inhibitory factor 1 (ATPIF1) in Wallerian degeneration and peripheral nerve regeneration. (PubMed, Exploration (Beijing))
Importantly, macrophages, not Schwann cells, are identified as key contributors to the delayed Wallerian degeneration in ATPIF1 knockout mice, and affect the overall outcome of peripheral nerve regeneration. These results shed light on the translational potential of ATPIF1 for improving peripheral nerve regeneration.
Journal
|
CCL2 (Chemokine (C-C motif) ligand 2) • ATP5IF1 (ATP Synthase Inhibitory Factor Subunit 1) • CCR2 (C-C Motif Chemokine Receptor 2)
almost2years
The ATPase Inhibitory Factor 1 (IF1) Contributes to the Warburg Effect and Is Regulated by Its Phosphorylation in S39 by a Protein Kinase A-like Activity. (PubMed, Cancers (Basel))
Moreover, we emphasize that IF1 is phosphorylated in vivo in its S39 by the c-AMP-dependent PKA activity of mitochondria to render an inactive inhibitor that is unable to interact with the enzyme, thus triggering the activation of ATP synthase. Overall, we discuss and challenge the results that argue against the role of IF1 as in vivo inhibitor of mitochondrial ATP synthase and stress that IF1 cannot be regarded solely as a pro-oncogenic protein because in some prevalent carcinomas, it prevents metastatic disease.
Review • Journal
|
ATP5IF1 (ATP Synthase Inhibitory Factor Subunit 1)
2years
HSK3486 Inhibits Colorectal Cancer Growth by Promoting Oxidative Stress and ATPase Inhibitory Factor 1 Activation. (PubMed, Dig Dis Sci)
Collectively, our findings revealed that HSK3486 induces oxidative stress, resulting in colorectal cancer cell apoptosis, making it a potential candidate therapeutic strategy for colorectal cancer.
Journal
|
BCL2 (B-cell CLL/lymphoma 2) • MCL1 (Myeloid cell leukemia 1) • CASP3 (Caspase 3) • ATP5IF1 (ATP Synthase Inhibitory Factor Subunit 1) • ANXA5 (Annexin A5)
|
BCL2 expression
2years
TR-57 Treatment of SUM159 Cells Induces Mitochondrial Dysfunction without Affecting Membrane Potential. (PubMed, Int J Mol Sci)
SUM159 cells incubated with TR57 up to 72 h retained the level of proteins facilitating the ATP transfer across the mitochondrial membranes: VDAC1 expression was not affected, while expression of ANT-1/2 and APC2 increased by 20% and 40%, respectively. Thus, our results suggest that although TR-57 treatment leads to complete inhibition of respiratory chain activity of SUM159 cells, hydrolysis of cytoplasmic ATP by reversal activity of FF-ATPase supports mitochondrial polarization.
Journal
|
ATP5IF1 (ATP Synthase Inhibitory Factor Subunit 1) • VDAC1 (Voltage Dependent Anion Channel 1)
2years
Dysregulated immune and metabolic pathways are associated with poor survival in adult acute myeloid leukemia with CEBPA bZIP in-frame mutations. (PubMed, Blood Cancer J)
Genes in mitochondrial complexes I (NDUFA12 and NDUFB6) and V (ATP5PB and ATP5IF1) were overexpressed and were associated with poorer survival, and the results were independently validated in the TARGET AML cohort. In conclusion, concurrent WT1 or DNMT3A mutations and a dysregulated immune and metabolic state were correlated with poor survival in patients with CEBPA, and upfront allogeneic transplantation may be indicated for better long-term disease control.
Journal
|
DNMT3A (DNA methyltransferase 1) • WT1 (WT1 Transcription Factor) • CEBPA (CCAAT Enhancer Binding Protein Alpha) • ATP5IF1 (ATP Synthase Inhibitory Factor Subunit 1) • IFI35 (Interferon Induced Protein 35) • IRF2 (Interferon Regulatory Factor 2) • IRF5 (Interferon Regulatory Factor 5)
|
DNMT3A mutation • CEBPA mutation
over2years
The Mitochondrial ATP Synthase/IF1 Axis in Cancer Progression: Targets for Therapeutic Intervention. (PubMed, Cancers (Basel))
In addition, we review recent findings stressing that mitochondria metabolism is the primary altered target in lung adenocarcinomas and that the ATP synthase/IF1 axis of OXPHOS is included in the most significant signature of metastatic disease. Finally, we stress that targeting mitochondrial OXPHOS in pre-clinical mouse models affords a most effective therapeutic strategy in cancer treatment.
Review • Journal
|
ATP5IF1 (ATP Synthase Inhibitory Factor Subunit 1)